UnitedHealthcare Carrier Screening Coverage Update

Coverage Criteria

Reproductive Carrier Screening - covered criteria

Covered when meeting the following panel-size and indication conditions:

Basic reproductive carrier screening: Panel of up to six genes (reproductive carrier screening) is proven and medically necessary.<=6 genes

See policy: Reproductive Carrier Screening Panels of up to six genes are proven and medically necessary (ACOG-aligned).

Expanded reproductive carrier screening with criteria: Panel of up to 15 genes is proven and medically necessary when the individual and/or their reproductive partner meets at least one of the following: (1) Ashkenazi Jewish ancestry (at least one parent or grandparent of Ashkenazi Jewish descent); OR (2) a biological first- or second-degree relative is affected by one or more of the conditions evaluated by the panel.<=15 genes with specified criteria

Coverage expands to 15 genes only with specified ancestry or affected relative criteria.

Not Medically Necessary

Unproven/not medically necessary panels: Reproductive carrier screening panels comprised of 16 or more genes are unproven and not medically necessary.>=16 genes

Considered a likely basis for denial due to insufficient evidence.

Non-reproductive indications: Carrier screening performed for indications other than reproductive carrier screening (as described in this policy) is unproven and not medically necessary.N/A

Carrier screening for all other indications is not covered.

Professional society guidance relevant to ECS

Professional society guidance summarized — these inform appropriate use of ECS:

ACOG general recommendations: Offer hemoglobinopathy testing to all individuals planning pregnancy or at the first prenatal visit if not previously tested; offer carrier screening for cystic fibrosis (CF) and spinal muscular atrophy (SMA) to all individuals who are pregnant or considering pregnancy. If ECS is considered, meet consensus criteria including disorder carrier frequency >1/100, well-defined childhood-onset phenotype with detrimental effect on quality of life, prenatal diagnosability with actionable implications, and exclusion of adult-onset conditions.

ACOG Committee Opinions (reaffirmed).

ACMG tiered recommendations: Adopt a tiered approach: Tier 1 = CF + SMA + risk-based; Tier 2 = >=1/100 carrier frequency; Tier 3 = >=1/200 carrier frequency and X-linked conditions (Tier 3 should be offered to all pregnant patients and those planning pregnancy); Tier 4 = <1/200 (consider only for consanguinity or specific family/personal history).

ACMG Practice Resource (Gregg et al., 2021)

NSGC position: NSGC (2023) conditionally recommends offering ECS to all individuals considering reproduction, pregnant individuals, and their partners, using shared decision-making that accounts for personal values; the recommendation is conditional and not tied to specific clinical criteria.

Reproductive carrier screening panels that include 16 or more genes are considered unproven and not medically necessary. The policy specifically notes that carrier screening performed for indications other than reproductive carrier screening (i.e., non-reproductive indications) is likewise considered not medically necessary. The policy also strongly recommends that reproductive carrier screening panels include testing for CFTR (cystic fibrosis) and SMN1 (spinal muscular atrophy).

Available studies of pan‑ethnic and expanded carrier screening (ECS) are largely observational and heterogeneous, with inconsistent methodologies, variable population sampling, and differing panel content that limit assessment of clinical impact. Many studies were rated poor or very poor quality or had a high risk of bias, and direct comparisons to minimal guideline-based screening are generally lacking. Additionally, differences in how laboratories calculate detection rates and recurrence risks contribute to discrepant results across reports, and larger panels may identify conditions with mild phenotypes that increase counseling and care burden.

The Royal College of Obstetricians and Gynaecologists (RCOG) concludes there is insufficient evidence to recommend routine testing of all prospective parents. RCOG recommends targeted, risk‑based screening for individuals at high risk and cautions that current ECS panels lack standardization; providers should understand panel composition and rely on clinicians with appropriate genetics expertise for interpretation.

The policy states that carrier screening panels for reproductive purposes that consist of 16 or more genes are considered unproven and not medically necessary. Similarly, carrier screening ordered for indications outside the reproductive screening context is deemed not medically necessary because evidence of clinical benefit in those settings is insufficient.

RCOG’s 2024 scientific impact statement advises against routine pan‑ethnic expanded carrier screening for all prospective parents due to limited evidence of benefit and the absence of standardized panel composition. The guidance highlights implications for universal screening programs, including potential overdiagnosis, variable clinical utility, and the need for specialist genetics interpretation and counseling before widespread implementation.

Covered Indications

Reproductive carrier screening for individuals planning pregnancy or currently pregnant; panels up to 6 genes (general) and up to 15 genes when ancestry or affected relative criteria met.

Individuals planning pregnancy or currently pregnant: Reproductive carrier screening is indicated for individuals planning pregnancy or who are currently pregnant to identify risk of autosomal recessive or X-linked conditions and inform reproductive decision-making.

ACOG recommends CF, SMA, and hemoglobinopathies screening for all women considering pregnancy or currently pregnant.

Panel size and criteria: Panels up to 6 genes are covered generally; panels up to 15 genes are covered when Ashkenazi Jewish ancestry or an affected first- or second-degree relative criteria are met.<=6 genes (general) OR <=15 genes with specified criteria

See policy coverage limits.

Preconception or prenatal carrier screening to identify carrier couples and inform reproductive decision-making

Eligibility Requirements

Carrier screening is indicated for individuals planning pregnancy or who are pregnant. Coverage supports smaller, guideline‑aligned panels: a basic reproductive carrier screen of up to 6 genes is considered proven and medically necessary, and panels of up to 15 genes are covered when the individual or their reproductive partner has Ashkenazi Jewish ancestry or when a biological first‑ or second‑degree relative is affected by one or more of the conditions evaluated by the panel.

The policy does not specify formal prior testing requirements. ACOG guidance referenced in the policy recommends offering hemoglobinopathy testing if no prior testing has been performed, and broadly recommends screening for CF and SMA for individuals who are pregnant or considering pregnancy regardless of prior testing status.

Provider Actions and Requirements

Prior Authorization

Check Prior Authorization

UnitedHealthcare may require prior authorization for services per plan contract or utilize third-party review tools (e.g., InterQual) to assist in administering benefits. Check the member's specific plan and contract for any prior authorization requirements before ordering testing.

Verify plan-specific prior authorization requirements and obtain authorization if required.
UnitedHealthcare may use third-party tools (e.g., InterQual) to guide coverage determinations.

Note

Plan / Contract Alignment Required

Coverage decisions must align with the federal, state, or contractual benefit plan requirements. This policy is informational; in the event of any conflict, the terms of the applicable federal, state, or contractual requirements govern.

Reference the member's federal, state, or contractual benefit plan when determining coverage.

Coding

Applicable procedure codes (reference)mixed

0400U	Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative.
81412	Ashkenazi Jewish associated disorders (e.g., Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1.
81443	Genetic testing for severe inherited conditions (e.g., cystic fibrosis, Ashkenazi Jewish-associated disorders [e.g., Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (e.g., ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH).
81479	Unlisted molecular pathology procedure

ACOG carrier frequency threshold

ACOG carrier frequency thresholdRecommend panels targeting conditions with a carrier frequency of at least 1/100 (corresponds to disease incidence ~1/40,000)

RationaleACOG identifies carrier frequency ≥1/100 as a consensus criterion when considering expanded carrier screening

Related guidanceACOG Committee Opinion 690 (2017, reaffirmed 2023) lists carrier frequency >1/100 among criteria for considering ECS

Carrier frequency thresholds — examples

ACOG example thresholdRecommend considering screening when the disorder carrier frequency is >1/100

ACMG tiered thresholds (summary)Tier 2: ≥1/100; Tier 3: ≥1/200 (includes Tier 2) and includes X-linked conditions; Tier 4: <1/200

Not Covered

Reproductive carrier screening panels comprised of 16 or more genes are categorized as not covered because the evidence is insufficient to demonstrate clinical benefit. Carrier screening performed for non‑reproductive indications is also listed as not covered.

The document excerpt does not list additional explicit tests that are not covered beyond the panel‑size and indication exclusions already stated; limitations in the evidence base and variable study quality are noted as factors limiting assessment.

RCOG’s statement that current evidence is insufficient to support routine pan‑ethnic ECS for all prospective parents implies that universal, population‑wide use of some expanded panels may not be supported and therefore could be considered not medically necessary without additional evidence and standardization.

Background

Carrier screening is used to identify asymptomatic individuals who may be at risk of passing autosomal recessive or X‑linked conditions to their children. Advances in next‑generation sequencing (NGS) permit multigene panels that vary widely in size and content. ACOG recommends that carrier screening for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies be offered to individuals who are pregnant or considering pregnancy, and the policy emphasizes inclusion of CFTR and SMN1 in reproductive carrier screening panels.

Definitions

Carrier Screening — definition

DefinitionGenetic testing performed on an individual without symptoms to determine whether they may have a genetic variant associated with a disorder that could be passed to biological children (ACOG).

PurposeIdentify asymptomatic carriers of autosomal recessive or X-linked conditions to inform reproductive decision-making.

ContextPan-ethnic and ancestry-based screening strategies are discussed in guidance cited by this policy.

First‑Degree Relative

DefinitionFirst-degree relatives include parents, siblings, and children (NCCN).

Coverage relevanceUp to 15-gene panels may be covered when a biological first-degree relative is affected by a condition evaluated by the panel.

OpenPayer

Carrier Testing Panels for Genetic Diseases (for New Mexico Only)